{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.3616.200.110.102.4019","meta":{"versionId":"5","lastUpdated":"2020-12-17T01:00:39.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4019","version":"20201217","name":"COVID19 ICD10PCS Value Set for Administration of Tocilizumab","status":"active","date":"2020-12-17T01:00:39-05:00","publisher":"Clinical Architecture","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","concept":[{"code":"XW033H5","display":"Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"},{"code":"XW043H5","display":"Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"}]}]},"expansion":{"identifier":"urn:uuid:7cd1cc8c-441a-4a2d-ae72-d613f37246c9","timestamp":"2022-06-10T06:23:37-04:00","total":2,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW033H5","display":"Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW043H5","display":"Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5"}]}}